Type of test : Microscopic examination
Normal findings
Absent genetic mutations
Test explanation and related physiology
Treatment for lung cancer has been empiric and based on histology of the tumor (i.e., adenocarcinoma, squamous, small cell). Subsets of non–small cell lung cancers (NSCLC) can be further defined at the molecular level by the presence of mutations that may occur in oncogenes (e.g., AKT1, ALK, BRAF, EGFR, HER2, KRAS, MEK1, MET, NRAS, PIK3CA, RET, and ROS1). Mutations in these oncogenes lead to activation of signaling proteins that induce and sustain tumor growth and therapy resistance. These mutations are not commonly found concurrently in the same tumor. Mutations can be found in all NSCLC histologies (including adenocarcinoma, squamous cell carcinoma [SCC], and large cell carcinoma) and in smokers and nonsmokers, alike.
Importantly, targeted drugs are currently available and still more are being developed that can inhibit the tumor development of these proteins and thereby inhibit tumor growth. Most significantly, the therapeutic importance of genes that encode pharmacologically targetable tyrosine kinases involved in growth factor receptor signaling, epidermal growth factor receptor (EGFR), and anaplastic lymphoma kinase (ALK) has changed the way these cancers are diagnosed and treated. At present, expert panels of oncologists and laboratory pathologists are attempting to develop consensus on the proper use of these tests in the treatment of local and metastatic lung cancer. Their use must take into account their cost of testing. Furthermore, it is important to recognize that these molecular tests do not only apply to lung cancer but may be applicable to many other epithelial cancers e.g., breast, gastrointestinal, and neuroendocrine.
Procedure and patient care
Before
* Explain the significance of the diagnostic data available.
* Explain the benefits of molecular testing in helping the physician and the patient make appropriate decisions regarding the use of surgery.
• Provide the patient with emotional support through the diagnostic period.
• Ensure that the patient’s insurance will cover this expensive testing.
During
• The pathologists will send a fresh or paraffin-embedded tumor specimen to a centralized laboratory.
• Results will be available in about 2 weeks.
After
* Provide education and support to patients as they evaluate their results.
Abnormal findings
- Known mutation of respective gene.